Aminohippurate Sodium

(Para-aminohippurate)

PreclinicalSmall molecule

Aminohippurate Sodium is one of 40 small molecule programs targeting Acute Kidney Injury. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

178 competitors in Acute Kidney Injury

#DrugCompanyPhaseTrials

Truphylline

TThe Searle Company Limited Pakistan

Phase 3

2 2

Epoetin Beta

Crestor

3 4

L-Alanyl/l-Glutamine

TTemple Therapeutics BV

Phase 3

1 5

Lescol

Novartis

Preclinical

1 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 7

Celexa

AbbVie

Preclinical

1 8

Proamatine

Takeda

Preclinical

1 9

Lexapro

AbbVie

Preclinical

1 10

Golytely

Bayer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Acute Kidney Injury

NCT05694624

Clinical

Trials by Indication[1]

ARB2 trials

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Completed·VVanderbilt University Medical Center·Phase 4·NCT04113109·46 enrolled

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

Completed·YYale University·Phase 4·NCT04649229·46 enrolled

Phase 11 trial

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01214993·38 enrolled

Acute Kidney Injury1 trial

Investigations Into Sepsis-associated Acute Kidney Injury

Recruiting·UUniversity Hospital of North Norway··NCT05694624·20 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

AMINOHIPPURATE SODIUM

NDA NDA005619

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Para-aminohippurate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Para-aminohippurate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Para-aminohippurate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA005619). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

Aminohippurate Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

ARB2 trials

Phase 11 trial

Acute Kidney Injury1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News